Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis - Report - MDSpire
Advertisement
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis
Clinical Report: Evaluating the Prognostic Role of ypN Status Following Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer
Overview
This systematic review and meta-analysis evaluates the prognostic significance of post-treatment nodal status (ypN) in patients with resectable non-small cell lung cancer (NSCLC) following neoadjuvant chemoimmunotherapy. The findings indicate that unfavorable ypN status is associated with significantly poorer overall and disease-free survival outcomes.
Background
Neoadjuvant chemoimmunotherapy has emerged as a critical treatment for resectable NSCLC, yet postoperative relapse remains a significant concern. Understanding the prognostic implications of ypN status can aid in identifying patients at higher risk for recurrence, thereby informing postoperative management strategies. This study aims to clarify the relationship between ypN status and survival outcomes in this patient population.
Data Highlights
Outcome
Pooled HR
95% CI
P-value
Overall Survival
4.75
2.38 - 9.47
< 0.00001
Disease-Free Survival
3.54
1.71 - 7.33
0.0007
Key Findings
Unfavorable ypN status is linked to significantly poorer overall survival (OS) outcomes.
The pooled hazard ratio for OS was 4.75, indicating a substantial increase in risk associated with unfavorable ypN status.
Disease-free survival (DFS) also showed a significant association with ypN status, with a pooled HR of 3.54.
Only one study provided data on recurrence-free survival (RFS), suggesting that combined major pathological response (MPR)-ypN classification may further stratify prognosis.
Findings should be interpreted cautiously due to the limited number of studies included in the analysis.
Clinical Implications
Clinicians should consider ypN status as a critical factor in postoperative risk stratification for patients with resectable NSCLC. This information may guide decisions regarding surveillance and potential treatment intensification for patients identified as high-risk based on their ypN status.
Conclusion
The study underscores the importance of ypN status in predicting survival outcomes in resectable NSCLC following neoadjuvant chemoimmunotherapy. Further prospective studies are needed to validate these findings and standardize pathological classifications.
